Felix John
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Felix John has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Heather Scharpenseel
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
10 shared publications - Lea Ruge
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
10 shared publications - Malte Verheyen
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
10 shared publications - Matthias Scheffler
Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
10 shared publications - Reinhard Büttner
Center for Integrated Oncology Aachen Köln Bonn Düsseldorf, Germany
10 shared publications - Richard Riedel
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
10 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses
Purpose:KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for approximately 1% to 7% of all KRAS mutations in non–small cell lung cancer (NSCLC). So far, the prognostic value of this cohort and its response to different treatment regimens remain unclear. Experimental Design:Between 2011 and 2023, diagnostic samples from patients with NSCLC were analyzed using next-generation sequencing. Molecular data were correlated with clinical records, and time-to-event analyses were performed using the Kaplan–Meier estimate. Results:Of the 8,862 analyzed probes, we identified 487 (5.5%) patients with KRAS Q61 mutations and further analyzed 365 patients. Most presented with Q61H (74.0%) and Q61L (20.8%) mutations that demonstrated distinct patterns in smoking history (7% vs. 3.3% never smokers, respectively) and co-mutational landscape. The most frequent co-mutations in Q61H were STK11 (45.8%), TP53 (32.1%), and KEAP1 (31.3%), whereas Q61L was mutually exclusive to STK11 and had a lower incidence of co-occurring KEAP1 mutations (11.5%). The median overall survival for the entire cohort was 12.3 months, with a favorable survival of 22.1 and 65.4 months for patients receiving combined chemoimmunotherapy and immunotherapy as first-line treatment, respectively. Real-world progression-free survival was significantly prolonged in patients receiving immunotherapy, either as monotherapy or combined therapy, versus chemotherapy (CTX) in the first-line setting (P < 0.01). Conclusions:KRAS Q61H and Q61L were the predominant mutational subtypes and demonstrated distinct molecular and clinical characteristics, with differences in the co-mutational landscape contributing to the observed survival differences between subtypes. Immunotherapy-based regimens were associated with more favorable outcomes compared with CTX, particularly in patients with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%), underscoring the importance of subtype-specific molecular characterization in clinical decision-making.See related commentary by Meazza Prina and Mezquita, p. 5014
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses
Purpose:KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for approximately 1% to 7% of all KRAS mutations in non–small cell lung cancer (NSCLC). So far, the prognostic value of this cohort and its response to different treatment regimens remain unclear. Experimental Design:Between 2011 and 2023, diagnostic samples from patients with NSCLC were analyzed using next-generation sequencing. Molecular data were correlated with clinical records, and time-to-event analyses were performed using the Kaplan–Meier estimate. Results:Of the 8,862 analyzed probes, we identified 487 (5.5%) patients with KRAS Q61 mutations and further analyzed 365 patients. Most presented with Q61H (74.0%) and Q61L (20.8%) mutations that demonstrated distinct patterns in smoking history (7% vs. 3.3% never smokers, respectively) and co-mutational landscape. The most frequent co-mutations in Q61H were STK11 (45.8%), TP53 (32.1%), and KEAP1 (31.3%), whereas Q61L was mutually exclusive to STK11 and had a lower incidence of co-occurring KEAP1 mutations (11.5%). The median overall survival for the entire cohort was 12.3 months, with a favorable survival of 22.1 and 65.4 months for patients receiving combined chemoimmunotherapy and immunotherapy as first-line treatment, respectively. Real-world progression-free survival was significantly prolonged in patients receiving immunotherapy, either as monotherapy or combined therapy, versus chemotherapy (CTX) in the first-line setting (P < 0.01). Conclusions:KRAS Q61H and Q61L were the predominant mutational subtypes and demonstrated distinct molecular and clinical characteristics, with differences in the co-mutational landscape contributing to the observed survival differences between subtypes. Immunotherapy-based regimens were associated with more favorable outcomes compared with CTX, particularly in patients with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%), underscoring the importance of subtype-specific molecular characterization in clinical decision-making.See related commentary by Meazza Prina and Mezquita, p. 5014
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses
Supplementary Figures and Tables
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses
Supplementary Figures and Tables
- Open Access
- 28 October 2026
- Published by Elsevier in JTO Clinical and Research Reports
Brief report: Tumor Inflammation-Associated Neurotoxicity (TIAN) in patients with small cell lung cancer treated with tarlatamab
- 28 October 2026
- Published by Elsevier in JTO Clinical and Research Reports
Open AccessBrief report: Tumor Inflammation-Associated Neurotoxicity (TIAN) in patients with small cell lung cancer treated with tarlatamab
- Open Access
- 11 August 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (8) , 38-43
Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass)
- 11 August 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (8) , 38-43
Open AccessRationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Purpose:KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood.Experimental Design:In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed.Results:The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months.Conclusions:KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Purpose:KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood.Experimental Design:In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed.Results:The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months.Conclusions:KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S2: Kaplan-Meier statistics on median real-world overall survival (rwOS) in different subgroups
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S2: Kaplan-Meier statistics on median real-world overall survival (rwOS) in different subgroups
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S3: In support of Fig. 5: PD-L1 expression in the different therapy subgroups
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S3: In support of Fig. 5: PD-L1 expression in the different therapy subgroups
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S1: Localization of genetic co-alterations (Created with cBioPortal [Scheffler M][https://www.cbioportal.org])
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S1: Localization of genetic co-alterations (Created with cBioPortal [Scheffler M][https://www.cbioportal.org])
- 10 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (22) , 5090-5099
Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses
Purpose: KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for approximately 1% to 7% of all KRAS mutations in non–small cell lung cancer (NSCLC). So far, the prognostic value of this cohort and its response to different treatment regimens remain unclear. Experimental Design: Between 2011 and 2023, diagnostic samples from patients with NSCLC were analyzed using next-generation sequencing. Molecular data were correlated with clinical records, and time-to-event analyses were performed using the Kaplan–Meier estimate. Results: Of the 8,862 analyzed probes, we identified 487 (5.5%) patients with KRAS Q61 mutations and further analyzed 365 patients. Most presented with Q61H (74.0%) and Q61L (20.8%) mutations that demonstrated distinct patterns in smoking history (7% vs. 3.3% never smokers, respectively) and co-mutational landscape. The most frequent co-mutations in Q61H were STK11 (45.8%), TP53 (32.1%), and KEAP1 (31.3%), whereas Q61L was mutually exclusive to STK11 and had a lower incidence of co-occurring KEAP1 mutations (11.5%). The median overall survival for the entire cohort was 12.3 months, with a favorable survival of 22.1 and 65.4 months for patients receiving combined chemoimmunotherapy and immunotherapy as first-line treatment, respectively. Real-world progression-free survival was significantly prolonged in patients receiving immunotherapy, either as monotherapy or combined therapy, versus chemotherapy (CTX) in the first-line setting (P < 0.01). Conclusions: KRAS Q61H and Q61L were the predominant mutational subtypes and demonstrated distinct molecular and clinical characteristics, with differences in the co-mutational landscape contributing to the observed survival differences between subtypes. Immunotherapy-based regimens were associated with more favorable outcomes compared with CTX, particularly in patients with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%), underscoring the importance of subtype-specific molecular characterization in clinical decision-making. See related commentary by Meazza Prina and Mezquita, p. 5014
- 10 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (22) , 5090-5099
Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses
Purpose: KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for approximately 1% to 7% of all KRAS mutations in non–small cell lung cancer (NSCLC). So far, the prognostic value of this cohort and its response to different treatment regimens remain unclear. Experimental Design: Between 2011 and 2023, diagnostic samples from patients with NSCLC were analyzed using next-generation sequencing. Molecular data were correlated with clinical records, and time-to-event analyses were performed using the Kaplan–Meier estimate. Results: Of the 8,862 analyzed probes, we identified 487 (5.5%) patients with KRAS Q61 mutations and further analyzed 365 patients. Most presented with Q61H (74.0%) and Q61L (20.8%) mutations that demonstrated distinct patterns in smoking history (7% vs. 3.3% never smokers, respectively) and co-mutational landscape. The most frequent co-mutations in Q61H were STK11 (45.8%), TP53 (32.1%), and KEAP1 (31.3%), whereas Q61L was mutually exclusive to STK11 and had a lower incidence of co-occurring KEAP1 mutations (11.5%). The median overall survival for the entire cohort was 12.3 months, with a favorable survival of 22.1 and 65.4 months for patients receiving combined chemoimmunotherapy and immunotherapy as first-line treatment, respectively. Real-world progression-free survival was significantly prolonged in patients receiving immunotherapy, either as monotherapy or combined therapy, versus chemotherapy (CTX) in the first-line setting (P < 0.01). Conclusions: KRAS Q61H and Q61L were the predominant mutational subtypes and demonstrated distinct molecular and clinical characteristics, with differences in the co-mutational landscape contributing to the observed survival differences between subtypes. Immunotherapy-based regimens were associated with more favorable outcomes compared with CTX, particularly in patients with high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥50%), underscoring the importance of subtype-specific molecular characterization in clinical decision-making. See related commentary by Meazza Prina and Mezquita, p. 5014